MarginsXMarginsX
Home › Markets › Health Care › BMRA

Biomerica Inc. (BMRA)

BMRA trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.32
-2.94% on the day
Market cap
$6.1M
Nano cap
Revenue · 2026
$4.5M
-16.2% on 2025
Net income · 2026
-$3.8M
-84.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-05-31, https://www.sec.gov/Archives/edgar/data/73290/000149315226040851/0001493152-26-040851-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-05-31.

Profile

FieldValue
TickerBMRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000073290
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2026

LineValue
Revenue$4.5M
Net income-$3.8M
Operating income-$5.3M
Net margin-84.8%
Operating margin-119.5%
Revenue growth-16.2%
Cash$1.3M
Total assets$6.8M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Warning signs

Cash runway
8.3 months
$2.7M cash at August 31, 2026
Share count, 1 year
+60.2%
2025-10-14 to 2026-10-15 · +118.7% over 3 years
Going-concern doubt
Yes
10-Q filed October 15, 2026
Insider net buying, 12 months
$158K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about our ability to continue as a going concern within twelve months following the issuance date of these financial statements."
10-Q 2026-10-15
Cash and burn$2.7M cash; operating cash flow -$989K a quarter.Report 2026-08-31
Shares outstanding4,598,968 (2026-10-15); 2,869,900 a year earlier; 16,821,646 three years earlier. 3y figure adjusted for splits (1-for-8 overall).Cover page 2026-10-15
Reverse splits, 3 years1; latest 1-for-8 on 2025-04-21Source 2025-04-21
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorHaskell & White LLP, Irvine, California, United StatesPCAOB Form AP 2026-09-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $158K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-08-31
$1.3M-$1.2M-$802K$2.7MNo debt tags$4.3M10-Q 2026-10-15
Q4 2026
2026-05-31
$875K-$1.1M-$912K$1.3MNo debt tags$4.5M10-K 2026-08-31
Q3 2026
2026-02-28
$987K-$1.3M-$1.3M$1.3MNo debt tags$4.3M10-Q 2026-04-13
Q2 2026
2025-11-30
$1.2M-$1.3M-$991K$2.5MNo debt tags$4.5M10-Q 2026-01-14
Q1 2026
2025-08-31
$1.4M$2K-$268K$3.1MNo debt tags$4.9M10-Q 2026-10-15
Q4 2025
2025-05-31
$749K-$1.5M-$662K$2.4MNo debt tags$5.3M10-K 2026-08-31
Q3 2025
2025-02-28
$1.1M-$1.2M-$1.0M$3.1MNo debt tags$5.7M10-Q 2026-04-13
Q2 2025
2024-11-30
$1.6M-$950K-$791K$2.4MNo debt tags$5.6M10-Q 2026-01-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-09-24
Latest annual report10-K/A2026-09-28
Latest quarterly / interim10-Q2026-10-15
Latest current report8-K2026-10-15
Latest proxyDEF 14A2026-10-16

Source: SEC EDGAR submissions feed, 605 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.5%
1 month-26.5%
3 months-16.0%
Year to date-46.0%
1 year-45.6%
From 52-week high-52.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
CDIOCardio Diagnostics Holdings Inc.$1.79-7.26%$5.3M
VNRXVolitionRX Limited$0.1998-13.13%$7.2M
TRIBTrinity Biotech plc$5.38-11.89%$4.4M
QCLSQ/C Technologies Inc.$0.3210+4.80%$2.6M
IMDXInsight Molecular Diagnostics Inc.$1.86-13.08%$60.9M
VRAXVirax Biolabs Group Limited$0.4480-26.87%$603K
ICCCImmuCell Corporation$11.42+6.23%$103.8M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier